Skip to content

Efficacy and Safety of Fospropofol Disodium for General Anesthesia Induction in Obese Patients

Efficacy and Safety of Fospropofol Disodium for General Anesthesia Induction in Obese Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105833
Enrollment
Unknown
Registered
2025-07-11
Start date
2025-07-14
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for obese patients

Interventions

Group CTBW:Fospropofol Disodium Induction based on TBW
Group FTBW:Fospropofol Disodium Induction based on TBW
Fospropofol Disodium group:Fospropofol Disodium Induction based on LBW

Sponsors

Gansu Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need to receive general anesthesia for elective surgery; 2. Age 18-65 years old, gender is not limited; 3. ASA Grading I./II/III; 4. Preoperative blood routine, coagulation function, liver and kidney function and other experimental examinations were generally normal; 5. Normal group: 18.5 kg/m^2=30kg/m^2; 6. Patients voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergy to eggs, soybeans and related products; 2. Allergy to the study drug or structurally similar drugs; 3. Family history of malignant hyperthermia; 4. Have a history of alcohol abuse or drug abuse; 5. Patients with severe abnormal liver and kidney function and severe cardiopulmonary failure; 6. Those who take psychotropic drugs and chronic analgesic drugs for a long time; 7. Participated in other drug clinical trials as a subject in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Secondary

MeasureTime frame
Hemodynamic parameters ;Sedation level and sedation onset time;PACU stay time ;Adverse reactions and satisfaction;Maintenance drug dosage;Blood indicators;

Countries

China

Contacts

Public ContactYan Wenjun

Gansu Provincial People's Hospital

13893370700@163.com+86 138 9337 0700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026